Brown Advisory Inc Ligand Pharmaceuticals Inc Transaction History

Brown Advisory Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$49.57 - $72.63 $384,514 - $563,390	7,757 New	7,757 $554,000
Q2 2019 Aug 12, 2019	SELL	$107.38 - $129.34 $2.96 Million - $3.57 Million	-27,568 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $1.28 Million - $1.73 Million	12,129 Added 78.56%	27,568 $3.47 Million
Q4 2018 Feb 13, 2019	BUY	$128.36 - $272.13 $877,725 - $1.86 Million	6,838 Added 79.5%	15,439 $2.09 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $223,850 - $290,959	-1,060 Reduced 10.97%	8,601 $2.36 Million
Q2 2018 Aug 10, 2018	BUY	$150.77 - $207.98 $260,078 - $358,765	1,725 Added 21.74%	9,661 $2 Million
Q1 2018 Jun 28, 2018	BUY	$138.63 - $182.62 $23,567 - $31,045	170 Added 2.19%	7,936 $1.31 Million
Q1 2018 May 14, 2018	SELL	$138.63 - $182.62 $118,805 - $156,505	-857 Reduced 9.94%	7,766 $1.28 Million
Q4 2017 Feb 12, 2018	SELL	$128.36 - $147.04 $38,764 - $44,406	-302 Reduced 3.38%	8,623 $1.18 Million
Q3 2017 Nov 13, 2017	BUY	$120.91 - $137.94 $39,779 - $45,382	329 Added 3.83%	8,925 $1.22 Million
Q2 2017 Aug 14, 2017	BUY	N/A	8,596	8,596 $1.04 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.